Irish dairy companies are expanding whey production as global demand rises alongside booming GLP-1 weight-loss drug use ...

Deal volume in 2026 is substantially outpacing last year, and activity is being driven by interest in cancer and autoimmune ...

Record-breaking quarter: Revenue jumped 56% to $19.79 billion in Q1 2026, with Mounjaro and Zepbound contributing $12.8 billion combined. New pill launch: Foundayo, Lilly’s first oral GLP-1 drug, saw ...

The two companies with the steepest increases market blockbuster medications that saw deep price cuts in 2026.

Gov. Mike Braun, alongside Eli Lilly and Company leaders and employees, on Wednesday celebrated the opening of Lilly Lebanon ...

Eli Lilly could appeal to both growth and income-oriented investors.

After losing the top spot in March to Johnson & Johnson’s immunology drug Tremfya, AbbVie’s rival med Skyrizi is back as the ...

In this video from the American Academy of Dermatology Annual Meeting, Lawrence F. Eichenfield, MD, discusses new treatment ...

Eli Lilly and Company (NYSE: LLY) is one of the best stocks to buy for the next 15 years. On May 7, Eli Lilly executed its ...

Eli Lilly’s Mounjaro has overtaken Keytruda as the world’s best-selling drug, reflecting booming global demand for obesity ...

While Pfizer is playing catch-up in the GLP-1 race, it has several irons in the fire that could turn its business around.

Clinical trials are the irreplaceable engine of drug development and a bedrock of modern medicine, yet patient enrollment ...